2026 Midterms Create an Opening and a Test for the Longevity Industry

The 2026 midterm election results give longevity companies new opportunities to shape federal research and drug development policy, but they will also bring greater scrutiny of the science, claims, and costs behind novel interventions. Democratic majorities in both chambers of the US Congress give the party control over committees, the appropriations process, oversight agendas, and the US Senate’s nomination confirmation process.

On

Control of the agenda, however, is not control of the outcomes. Most standalone Democratic priorities, including drug pricing, research funding, and US Food and Drug Administration (FDA) reform legislation, will still need Republican votes to clear the Senate and the president’s signature to become law. That makes must-pass vehicles critical. Government funding bills and expiring authorizations, such as the eighth reauthorization of the Prescription Drug User Fee Act (PDUFA VIII), must be enacted on a deadline and typically move with bipartisan support, making them the most realistic path for policy riders and program changes over the next two years.

For more on the implications of the midterm results, read the AFS 2026 Election Analysis.

Highlights for the Longevity Industry

  • PDUFA VIII is a near-term opportunity. The September 2027 prescription drug user fee reauthorization is a must-pass bill that could advance policies involving biomarkers, surrogate endpoints, innovative trial designs, real-world evidence, and potentially multi-disease therapies. The House Energy and Commerce Committee and the Senate Health, Education, Labor, and Pensions Committee will be the primary drivers behind the reauthorization but will work with the FDA on the technical details of the bill language.
  • NIH and aging research may receive stronger congressional support. Expect pressure to protect funding for the National Institutes of Health (NIH) and the National Institute on Aging (NIA), along with oversight of grant cancellations, peer review, agency staffing levels, and political involvement in federally funded scientific research. Republican members of Congress may feel emboldened to voice their support for public health funding given that President Trump has entered the lame-duck portion of his presidency.
  • Oversight will increase, as will opportunities for engagement. Democratic-led committees are likely to examine decision-making at the US Department of Health and Human Services (HHS) and the FDA, while drug pricing, affordability, scientific integrity, and agency staffing remain prominent concerns. Many Democrats campaigned on making health care more affordable and will be under pressure to deliver tangible cost reductions. Access is a related priority: some critics frame longevity as a market for the wealthy, and lawmakers are likely to scrutinize who can actually obtain interventions that extend healthspan. Longevity innovators that can show how their products lower costs and reach broad patient populations will have opportunities to present solutions.
  • Consumer-facing companies should tighten evidence and claims practices. Clinics, telehealth platforms, diagnostics companies, supplement and peptide sellers, and other wellness businesses should expect continued scrutiny from the FDA and the Federal Trade Commission (FTC) regarding product safety and unsubstantiated health claims.

FDA Modernization

For longevity biotechnology, the most consequential near-term legislation is PDUFA VIII. The current authorization expires in September 2027, requiring Congress to act for the FDA to continue collecting user fees that support drug application reviews.

The proposed PDUFA VIII framework already includes initiatives relevant to longevity developers, including multi-divisional FDA meetings, biomarker qualifications, increased use of real-world evidence, digital health technologies, model-informed drug development, and innovative clinical trial designs.

The longevity community is also advancing a proposed Multi-Disease Therapeutic Designation (MDTD) for therapies that target shared mechanisms underlying multiple age-related diseases rather than a single indication. The concept would provide coordinated review across FDA divisions and greater flexibility for qualified aging biomarkers. MDTD remains conceptual, but PDUFA VIII can lay the groundwork by building the review tools MDTD needs and giving stakeholders a forum to show where single-disease frameworks do not fit therapies that target aging itself.

Research Funding

Democratic control of the House and Senate will likely strengthen congressional efforts to protect biomedical research funding and scrutinize political involvement in scientific grantmaking. Longevity stakeholders have warned that grant cancellations, funding pauses, and uncertainty surrounding peer review can disrupt long-term scientific studies. Congressional Democrats will be eager to restore public health funding, which presents an opportunity for stakeholders to engage with the incoming majority on how to rebuild investment in public health and longevity research.

Funding is not guaranteed, however. The Trump Administration’s FY 2027 HHS budget request proposes approximately $4.2 billion for the NIA, about 6.9% below the FY 2026 enacted level. The request does include $25 million for geroscience research on biomarkers of aging and disease, signaling continued HHS interest in the field. NIH and NIA appropriations will therefore be a significant advocacy opportunity in the FY 2027 cycle.

Greater Scrutiny for the Consumer Longevity Market

The election also carries risks for consumer-facing longevity businesses. The FTC remains focused on unsubstantiated health claims, while the FDA has increased its attention to peptides, compounding, and products marketed for research use. Companies should prepare for stronger congressional health oversight that could heighten attention to evidence standards, product safety, advertising claims, affordability, and regulatory gray areas.

Key Takeaways: What Longevity Companies Should Watch

The key opportunities longevity companies have to engage in federal policy for 2027–2028 are:

  • PDUFA VIII. 
  • NIH and NIA appropriations. 
  • FDA staffing and leadership. 
  • Congressional oversight of HHS and the FDA. 
  • FDA and FTC enforcement involving peptides and consumer health claims.

Companies should document the evidentiary basis for product and policy assertions to build a clear narrative connecting healthspan innovation to lower chronic disease spending, better patient outcomes, broader patient access, and reduced long-term burden on the health system. That message will resonate with policymakers who have committed to making health care more affordable and accessible. The election opens a meaningful advocacy window, but companies will need credible science and thoughtful engagement to take advantage of it.

Contacts

Continue Reading